Changes in bone mineral density differ between gonadotrophin-releasing hormone analogue- and surgically castrated men with prostate cancer: A prospective, controlled, parallel-group study

Scandinavian Journal of Urology and Nephrology

Volumn 38, Issue 2, 2004, Pages 148-152

  Bergström, Ingrid ^a   Gustafsson, Hans ^b   Sjöberg, Kerstin ^c   Arver, Stefan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Närsjukhus Taby Taby   (Sweden)

^c DANDERYD HOSPITAL   (Sweden)

Author keywords

Bone mineral density; Medical castration; Prostate cancer; Surgical castration

Indexed keywords

GONADORELIN; GONADORELIN DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; BONE DENSITY; BONE MINERAL; CANCER HORMONE THERAPY; CANCER REGRESSION; CASTRATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG INDICATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR NECK; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; INTERMETHOD COMPARISON; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CARCINOMA; TESTOSTERONE BLOOD LEVEL; URINARY TRACT DISEASE;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE NEOPLASMS; CASE-CONTROL STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 1942518362     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365590310018810     Document Type: Article

References (24)

1. Johansson J-E, Hellström M, Gustafsson O, Stattin P, Hellström K, Nilsson J, et al. The register of prostatic cancer in Sweden 1996-1999. May 2001 ROC, Uppsala, Sweden.
2. Helgesen F, Holmberg L, Johansson JE, Bergström R, Adami HO. Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of non-lethal tumours. J Natl Cancer Inst 1996; 88: 1216-21.
3. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7.
4. Henriksson P, Edhag O. Cost-effectiveness comparison of oestrogen therapy and orchidectomy in patients with prostatic cancer. Int J Technol Assess Health Care 1987; 3: 523-9.
5. Kaisary AV, Tyrell CJ, Peeling WB, Griffiths K. Comparison of LHRH analogue with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991; 67: 502-8.
6. Johansson J-E, Andersson S-O, Holmberg L, Bergström L. Primary orchiectomy versus estrogen therapy in advanced prostatic cancer - a randomized study: results after 7-10 years followup. J Urol 1991; 145: 519-23.
7. Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol 1997; 32: 391-5.
8. Crawford ED, Eisenberg MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-24.
9. Murphy S, Khaw K, Cassidy A, Compston JE. Sex hormones and bone mineral density in elderly men. Bone Miner 1993; 20: 133-40.
10. Kanis JA, Melton III J, Christiansen C, Johnston C, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 1137-41.
11. Perry III HM, Morley JE. Osteoporosis in men: are we ready to diagnose and treat? Curr Rheumatol 2001; 3: 240-4.
12. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2002; 87: 589-98.
13. Summers GD. Osteoporosis in men. Radiography 2001; 7: 11923.
14. Pande I, Frances RM. Osteoporosis in men. Best Pract Res Clin Rheumatol 2001; 15: 415-29.
15. Davidson CW, Merrilees MJ, Wilkinson TJ, McKie JS, Gilchrist NL. Hip fracture mortality and morbidity - can we do better? N Z Med J 2001; 114: 329-32.
16. Diamond T, Sambrook P, Williamson M, Flicker L, Nowson C, Fiatarone-Singh M, et al. Men and osteoporosis. Aust Fam Physician 2001; 8: 781-5.
17. Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink DJ. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 1989; 69: 523-7.
18. Eriksson S, Eriksson A, Stege R, Carlström K. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 1994; 57: 97-9.
19. Stoch SA, Parker RA, Chen L, Bubley G, Ko YJ, Vincelette A. Bone loss in men with prostate cancer treated with gonadotropine releasing hormone agonists. J Clin Endocrinol Metab 2001; 86: 2787-91.
20. Kiralti BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001; 57: 127-32.
21. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niaszi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181-6.
22. Townsend MF, Holt Sanders W, Northway RO, Graham SD. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 1997; 79: 545-9.
23. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157: 439-44.
24. Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Goldman H, Resnick M. Skeletal fractures associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001; 166: 1724-8.